Terminated
PHASE2
INTERVENTIONAL
NCT01122511
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
Interventions
Name:
700 ug dexamethasone
Type:
DRUG
Description:
Intravitreal injection of 700 ug dexamethasone into study eye
Name:
ranibizumab
Type:
BIOLOGICAL
Description:
Intravitreal injection of ranibizumab into study eye
Name:
sham
Type:
OTHER
Description:
Sham needle-less injection administered in the study eye
Primary Outcomes
Measure:
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
TimeFrame:
Baseline, Month 12
Description:
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Trial Information
NCT ID
NCT01122511
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Allergan
Last Updated
December 15, 2025